At the completion of this educational session, participants should be able to:
- Understand the evolving recommendations for when to start antiretroviral therapy (ART) for HIV disease.
- Identify optimal initial ART regimens.
- Know strategies for treatment-experienced patients.
- Learn about new antiretroviral agents for the treatment of HIV disease.
Roy M. (Trip) Gulick is Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York City. He currently serves as Principal Investigator of the Cornell HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), sponsored by the National Institutes of Health. He also serves as a Board Member of the International AIDS Society- USA, and as a member of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services.
To obtain CME credit for this and other PRN programs, please visit the PRN Video Channel
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.